Treatment with a COX-2 inhibitor reduced PD-L1 expression in both MSI-H and MSS CRC cell lines, reinforcing a potential immunoregulatory role of COX-2 that warrants further therapeutic exploration. The gene discussed is PTGS2; the disease is colorectal carcinoma.